First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors

Omid Hamid, Alberto A. Chiappori, John A. Thompson, Toshihiko Doi, Siwen Hu-Lieskovan, Ferry A.L.M. Eskens, Willeke Ros, Adi Diab, Jean Philippe Spano, Naiyer A. Rizvi, Jeffrey S. Wasser, Eric Angevin, Patrick A. Ott, Alison Forgie, Wenjing Yang, Cen Guo, Jeffrey Chou, Anthony B. El-Khoueiry

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Fingerprint

Dive into the research topics of 'First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology